The math on healthcare denials has become impossible to ignore. Initial denial rates hit 11.81% in 2024 — a 2.4% increase from the prior year, according to Kodiak Solutions benchmarking data — and hospitals now spend nearly $18 billion annually overturning claims they should have been paid on the first submission. Meanwhile, hospitals lose an average of 4.8% of net revenue to denials — tens of millions of dollars annually for large systems,  per HFMA's Pulse Survey. Against that backdrop, the structure of an RCM vendor relationship matters as much as the vendor itself. [Healthcare Financial Management Association]

Outcome-based RCM partnerships — arrangements where vendor compensation is tied to measurable financial results rather than volume of work performed — are gaining traction precisely because the financial stakes of underperformance have risen so sharply. But tying payment to outcomes is not a structure. It's a starting point. Getting that structure right requires answering three foundational questions: which outcomes matter, where accountability can be clearly enforced, and how the partnership will be governed over time.

Define the Financial Outcomes Before Defining the Contract

The most common mistake in outcome-based contracting is selecting metrics that are easy to measure rather than metrics that reflect actual financial performance. Many organizations reach for gross collection rate or total denial volume — figures that look meaningful on a dashboard but can be manipulated by scope, timing, or claim mix changes.

Outcomes worth contracting around share one characteristic: the financial impact is directly attributable to vendor action and independently verifiable. Functions where this is feasible include denial recovery and appeals, underpayment resolution, no-response claim follow-up, aged A/R recovery, and cash acceleration on specific claim populations.

Underpayment recovery deserves particular attention. Providers lose 1% to 11% of net patient revenue annually to underpayments alone. Practices conducting quarterly payer variance reviews collect 8–12% more per claim than those that don't  — a $300,000 annual difference on a $3M practice, per HFMA's 2024 Revenue Cycle Survey. For organizations that have not systematically compared remittances against contracted rates at the CPT and modifier level, underpayment recovery is one of the highest-yield, most directly attributable functions available for outcome-based contracting. ‍

Similarly, denial appeals carry clear attribution. 54.3% of denied claims from private payers are ultimately overturned on appeal,  per Premier Inc. research — suggesting billions of dollars in legitimate reimbursement that payers initially withhold. The cost of not pursuing those appeals is concrete: appealing denied claims costs an average of $118 per claim  according to MGMA, but the alternative is accepting those denials as permanent write-offs. A vendor compensated on recovered value has a fundamentally different incentive structure than one paid for claim volume.

Match the Pricing Model to the Function

Not every revenue cycle function belongs in an outcome-based structure, and forcing the wrong model onto the wrong function creates misaligned incentives that hurt both sides. The practical framework is simpler than most organizations make it:

Functions with direct, traceable financial impact are the strongest candidates for contingency or performance-based pricing. Denial management and appeals, underpayment recovery, aged A/R liquidation, and no-response claim resolution all clear this bar. The financial impact of work performed can be calculated from remittance data, and attribution is defensible.

Functions that require operational continuity and quality oversight — coding, patient access, eligibility verification, payment posting — are better suited to hybrid structures. These functions affect downstream financial performance, but the relationship between a specific vendor action and a specific dollar collected is harder to isolate. A hybrid structure applies performance incentives selectively while keeping foundational workflows stable.

The practical implication: a hospital contracting with an RCM partner for end-to-end services should not apply the same pricing logic across the board. Front-end patient access work warrants different accountability structures than back-end denial recovery. Treating them identically either underincentivizes the work where contingency pricing makes sense, or creates perverse incentives in workflows where quality and compliance matter more than raw recovery volume.

Build Governance That Enforces Accountability

An outcome-based contract is only as durable as its governance structure. Without agreed definitions, attribution rules, and reporting cadences, financial disputes are inevitable — and disputes cost time and damage the partnership.

Effective governance for outcome-based RCM partnerships requires five elements working together:

Performance metrics with agreed definitions. What counts as a "recovered" denial? At what point is an underpayment considered resolved? These definitions need to be locked at contract execution, not negotiated after the fact when there's money on the table.

Attribution methodology. When a claim is paid after multiple touchpoints — initial submission, denial, appeal, re-billing — which actions count toward vendor performance? Clear attribution rules prevent the most common source of contract disputes.

Reporting infrastructure. Real-time or near-real-time data access matters. 88% of revenue cycle leaders surveyed by Guidehouse and HFMA cite payer challenges as their top stressor  — organizations cannot manage what they cannot see. Both parties need visibility into the same data. [Beckers Hospital Review]

Shared oversight processes. Governance is not an annual review. Operational performance should be reviewed frequently at the working level; executive governance should evaluate ROI, strategic priorities, and contract structure quarterly.

Compliance safeguards. Outcome-based incentives can create pressure to pursue aggressive appeal strategies or prioritize high-value claims at the expense of compliance. The governance structure needs audit readiness built in from the start, not bolted on when a payer audit surfaces.

Use Analytics to Shift From Recovery to Prevention

The ceiling on outcome-based RCM is not recovery. It's prevention. Organizations that limit the scope of their partnerships to retrospective denial recovery leave the majority of the opportunity on the table.

Automated claim-scrubbing and predictive validation can prevent up to 85% of avoidable denials, reducing administrative cost per claim by nearly one-quarter,  per the Deloitte Center for Health Solutions' 2024 report on revenue cycle reinvention. AI-powered RCM platforms can demonstrate measurable returns within 40 days, with most organizations achieving positive ROI within 12 months,  and organizations implementing RCM automation experienced a 27% decrease in cost-to-collect and a 6% increase in net patient revenue,  per Black Book Research. [Healthcare Financial Management Association]

The shift from reactive to proactive isn't a technology decision alone — it's a partnership design decision. Vendors with access to payer-level denial trend data, authorization pattern analysis, and underpayment detection tools can identify leakage earlier in the cycle, before claims leave the building. That capability is worth structuring into the contract explicitly: not just as a recovery function, but as a prevention mandate with its own performance metrics.

True AR days increased 5.2% year-over-year in 2024, driven by rising request-for-information denials and slower payer responses.  Organizations that are only managing AR at the back end are fighting a rearguard action against a problem their front-end workflows are generating. The partnership model needs to address both.

Evaluate the Five Structural Questions Before Signing

Before committing to an outcome-based or hybrid RCM structure, healthcare organizations should have clear answers to these questions — not working assumptions, but documented positions agreed upon with the prospective partner.

Which functions belong in an outcome-based structure? Segment the revenue cycle by attribution clarity. Functions where dollar impact can be independently verified from remittance data belong in contingency arrangements. Functions where quality and compliance drive long-term performance belong in hybrid or fee-based structures with performance overlays.

How will financial impact be measured? Define the baseline. Recovery against what? Compared to what prior period? On what claim population? Vendors who resist detailed baseline discussions before contract execution are telling you something.

What reporting infrastructure is required? Real-time visibility into claim status, denial reasons, appeal outcomes, and payment variance is not a negotiating point — it's a structural requirement. Build it into the statement of work.

How will compliance and audit readiness be maintained? Performance incentives create pressure. The governance structure needs to include regular audit sampling, denial reason code analysis, and payer communication review to ensure that recovery tactics remain defensible.

Where does a hybrid model make more sense? For most organizations, the answer is: more places than they initially expect. Hybrid structures are not a compromise — they're the right tool for functions where outcome attribution is complex.

ENTER's platform was built for exactly this kind of accountability. ENTER integrates AI-driven denial detection, underpayment analysis, and payer contract management into a single revenue cycle environment — giving organizations the data infrastructure to enforce outcome-based contracts with confidence and catch revenue leakage before it compounds. If you're evaluating how to structure your next RCM partnership, visit enter.health to see how measurable financial accountability works in practice.

FAQ: Designing Outcome-Based RCM Partnerships

Which revenue cycle functions are best suited for outcome-based pricing?
Functions with direct, traceable financial attribution — denial management and appeals, underpayment recovery, no-response claim follow-up, and aged A/R liquidation — are the strongest candidates. These areas allow recovery to be measured from remittance data and attributed to specific vendor actions, making contingency pricing structures defensible for both parties.

When does a hybrid RCM model make sense?
A hybrid model applies when some functions carry direct financial attribution while others require operational continuity, quality oversight, or longer measurement cycles. Coding, patient access, and eligibility verification typically fall into this category — performance overlays can be added, but a pure outcome-based structure creates misaligned incentives in workflows where compliance matters as much as volume.

What governance elements are non-negotiable in an outcome-based contract?
At minimum: agreed metric definitions, a documented attribution methodology, shared reporting infrastructure, regular operational review cadences, and built-in compliance safeguards. Governance disputes — not performance disputes — are the most common reason outcome-based RCM partnerships fail.

How do analytics change the value of an outcome-based RCM partnership?
Analytics shift the partnership from reactive recovery to proactive prevention. Vendors with denial trend data and predictive tools can identify claim risk before submission, not just after denial — which is where the largest financial opportunity sits.

What baseline data does an organization need before structuring an outcome-based contract?
At minimum: 12–24 months of remittance data segmented by payer and denial reason, current denial rate by payer and claim type, existing A/R aging by bucket, and a contract management baseline showing expected versus actual payer reimbursement rates. Without this data, there is no credible baseline against which vendor performance can be measured.

‍